ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Research Report 2025
Published Date: July 2025
|
Report Code: QYRE-Auto-32F944
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Glucagon like Peptide 2 GLP 2 Agonist Market Research Report 2020
BUY CHAPTERS

Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Research Report 2025

Code: QYRE-Auto-32F944
Report
July 2025
Pages:73
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Takeda Pharmaceuticals

Glucagon-like Peptide-2 (GLP-2) Agonist Market Size

The global market for Glucagon-like Peptide-2 (GLP-2) Agonist was valued at US$ 996 million in the year 2024 and is projected to reach a revised size of US$ 2777 million by 2031, growing at a CAGR of 16.0% during the forecast period.

Glucagon-like Peptide-2 (GLP-2) Agonist Market

Glucagon-like Peptide-2 (GLP-2) Agonist Market

Teduglutide (brand names Gattex in the US and Revestive in Europe) is a 33-membered polypeptide and glucagon-like peptide-2 (GLP-2) analog that is used for the treatment of short bowel syndrome.
The Teduglutide market is primarily driven by the demand for innovative therapies to address short bowel syndrome (SBS) and improve the quality of life for affected patients. Teduglutide is a medication used to treat SBS, a condition characterized by impaired intestinal function due to surgical resection or congenital anomalies. The limited treatment options for SBS, coupled with advancements in gastrointestinal medicine and patient-centric care, contribute to market growth. Moreover, the demonstrated efficacy of Teduglutide in reducing dependence on parenteral nutrition and enhancing nutrient absorption further propels adoption. However, challenges include managing potential side effects and addressing patient access issues. Navigating regulatory approvals, optimizing treatment regimens, and ensuring long-term safety and efficacy are ongoing concerns. The market"s success relies on continuous research in gastrointestinal disorders, collaborations between pharmaceutical manufacturers and gastroenterologists, and comprehensive patient education on the benefits and potential risks of Teduglutide treatment while addressing the evolving challenges associated with SBS management and treatment accessibility.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Glucagon-like Peptide-2 (GLP-2) Agonist, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Glucagon-like Peptide-2 (GLP-2) Agonist.
The Glucagon-like Peptide-2 (GLP-2) Agonist market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Glucagon-like Peptide-2 (GLP-2) Agonist market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Glucagon-like Peptide-2 (GLP-2) Agonist manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Glucagon-like Peptide-2 (GLP-2) Agonist Market Report

Report Metric Details
Report Name Glucagon-like Peptide-2 (GLP-2) Agonist Market
Accounted market size in year US$ 996 million
Forecasted market size in 2031 US$ 2777 million
CAGR 16.0%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
  • Gattex
  • Revestive
Segment by Application
  • Hospital
  • Pharmacy
  • Other
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Takeda Pharmaceuticals
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Glucagon-like Peptide-2 (GLP-2) Agonist manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Glucagon-like Peptide-2 (GLP-2) Agonist in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

How fast is Glucagon-like Peptide-2 (GLP-2) Agonist Market growing?

Ans: The Glucagon-like Peptide-2 (GLP-2) Agonist Market witnessing a CAGR of 16.0% during the forecast period 2025-2031.

What is the Glucagon-like Peptide-2 (GLP-2) Agonist Market size in 2031?

Ans: The Glucagon-like Peptide-2 (GLP-2) Agonist Market size in 2031 will be US$ 2777 million.

Who are the main players in the Glucagon-like Peptide-2 (GLP-2) Agonist Market report?

Ans: The main players in the Glucagon-like Peptide-2 (GLP-2) Agonist Market are Takeda Pharmaceuticals

What are the Application segmentation covered in the Glucagon-like Peptide-2 (GLP-2) Agonist Market report?

Ans: The Applications covered in the Glucagon-like Peptide-2 (GLP-2) Agonist Market report are Hospital, Pharmacy, Other

What are the Type segmentation covered in the Glucagon-like Peptide-2 (GLP-2) Agonist Market report?

Ans: The Types covered in the Glucagon-like Peptide-2 (GLP-2) Agonist Market report are Gattex, Revestive

Recommended Reports

GLP-1 and Peptide Therapeutics

Short Bowel & Intestinal

Metabolic & Obesity Drugs

1 Glucagon-like Peptide-2 (GLP-2) Agonist Market Overview
1.1 Product Definition
1.2 Glucagon-like Peptide-2 (GLP-2) Agonist by Type
1.2.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Value Comparison by Type (2024 VS 2031)
1.2.2 Gattex
1.2.3 Revestive
1.3 Glucagon-like Peptide-2 (GLP-2) Agonist by Application
1.3.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Value by Application (2024 VS 2031)
1.3.2 Hospital
1.3.3 Pharmacy
1.3.4 Other
1.4 Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Size Estimates and Forecasts
1.4.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue 2020-2031
1.4.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales 2020-2031
1.4.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Glucagon-like Peptide-2 (GLP-2) Agonist Market Competition by Manufacturers
2.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Manufacturers (2020-2025)
2.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Glucagon-like Peptide-2 (GLP-2) Agonist, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Glucagon-like Peptide-2 (GLP-2) Agonist, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Glucagon-like Peptide-2 (GLP-2) Agonist, Product Type & Application
2.7 Global Key Manufacturers of Glucagon-like Peptide-2 (GLP-2) Agonist, Date of Enter into This Industry
2.8 Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Competitive Situation and Trends
2.8.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Glucagon-like Peptide-2 (GLP-2) Agonist Players Market Share by Revenue
2.8.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Scenario by Region
3.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region: 2020-2031
3.2.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region: 2020-2025
3.2.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region: 2026-2031
3.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Region: 2020-2031
3.3.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Region: 2020-2025
3.3.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Region: 2026-2031
3.4 North America Glucagon-like Peptide-2 (GLP-2) Agonist Market Facts & Figures by Country
3.4.1 North America Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2020-2031)
3.4.3 North America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Market Facts & Figures by Country
3.5.1 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2020-2031)
3.5.3 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Market Facts & Figures by Region
3.6.1 Asia Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region (2020-2031)
3.6.3 Asia Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Glucagon-like Peptide-2 (GLP-2) Agonist Market Facts & Figures by Country
3.7.1 Latin America Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2020-2031)
3.7.3 Latin America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Market Facts & Figures by Country
3.8.1 Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2020-2031)
3.8.3 Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2020-2031)
4.1.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2020-2025)
4.1.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2026-2031)
4.1.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Type (2020-2031)
4.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Type (2020-2031)
4.2.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Type (2020-2025)
4.2.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Type (2026-2031)
4.2.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Type (2020-2031)
4.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Price by Type (2020-2031)
5 Segment by Application
5.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2020-2031)
5.1.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2020-2025)
5.1.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2026-2031)
5.1.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Application (2020-2031)
5.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Application (2020-2031)
5.2.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Application (2020-2025)
5.2.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Application (2026-2031)
5.2.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Application (2020-2031)
5.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Takeda Pharmaceuticals
6.1.1 Takeda Pharmaceuticals Company Information
6.1.2 Takeda Pharmaceuticals Description and Business Overview
6.1.3 Takeda Pharmaceuticals Glucagon-like Peptide-2 (GLP-2) Agonist Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Takeda Pharmaceuticals Glucagon-like Peptide-2 (GLP-2) Agonist Product Portfolio
6.1.5 Takeda Pharmaceuticals Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Glucagon-like Peptide-2 (GLP-2) Agonist Industry Chain Analysis
7.2 Glucagon-like Peptide-2 (GLP-2) Agonist Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Glucagon-like Peptide-2 (GLP-2) Agonist Production Mode & Process Analysis
7.4 Glucagon-like Peptide-2 (GLP-2) Agonist Sales and Marketing
7.4.1 Glucagon-like Peptide-2 (GLP-2) Agonist Sales Channels
7.4.2 Glucagon-like Peptide-2 (GLP-2) Agonist Distributors
7.5 Glucagon-like Peptide-2 (GLP-2) Agonist Customer Analysis
8 Glucagon-like Peptide-2 (GLP-2) Agonist Market Dynamics
8.1 Glucagon-like Peptide-2 (GLP-2) Agonist Industry Trends
8.2 Glucagon-like Peptide-2 (GLP-2) Agonist Market Drivers
8.3 Glucagon-like Peptide-2 (GLP-2) Agonist Market Challenges
8.4 Glucagon-like Peptide-2 (GLP-2) Agonist Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Takeda Pharmaceuticals
List of Tables
 Table 1. Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Glucagon-like Peptide-2 (GLP-2) Agonist Average Price (USD/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Glucagon-like Peptide-2 (GLP-2) Agonist, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Glucagon-like Peptide-2 (GLP-2) Agonist, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Glucagon-like Peptide-2 (GLP-2) Agonist, Product Type & Application
 Table 12. Global Key Manufacturers of Glucagon-like Peptide-2 (GLP-2) Agonist, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Glucagon-like Peptide-2 (GLP-2) Agonist by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Glucagon-like Peptide-2 (GLP-2) Agonist as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region (2020-2025) & (K Units)
 Table 18. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Region (2020-2025)
 Table 19. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region (2026-2031) & (K Units)
 Table 20. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Region (2026-2031)
 Table 21. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Region (2020-2025)
 Table 23. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Region (2026-2031)
 Table 25. North America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2020-2025) & (K Units)
 Table 27. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2026-2031) & (K Units)
 Table 28. North America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales (K Units) by Type (2020-2025)
 Table 51. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales (K Units) by Type (2026-2031)
 Table 52. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Type (2020-2025)
 Table 53. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Type (2026-2031)
 Table 54. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Type (2020-2025)
 Table 57. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Type (2026-2031)
 Table 58. Global Glucagon-like Peptide-2 (GLP-2) Agonist Price (USD/Unit) by Type (2020-2025)
 Table 59. Global Glucagon-like Peptide-2 (GLP-2) Agonist Price (USD/Unit) by Type (2026-2031)
 Table 60. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales (K Units) by Application (2020-2025)
 Table 61. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales (K Units) by Application (2026-2031)
 Table 62. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Application (2020-2025)
 Table 63. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Application (2026-2031)
 Table 64. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Application (2020-2025)
 Table 67. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Application (2026-2031)
 Table 68. Global Glucagon-like Peptide-2 (GLP-2) Agonist Price (USD/Unit) by Application (2020-2025)
 Table 69. Global Glucagon-like Peptide-2 (GLP-2) Agonist Price (USD/Unit) by Application (2026-2031)
 Table 70. Takeda Pharmaceuticals Company Information
 Table 71. Takeda Pharmaceuticals Description and Business Overview
 Table 72. Takeda Pharmaceuticals Glucagon-like Peptide-2 (GLP-2) Agonist Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 73. Takeda Pharmaceuticals Glucagon-like Peptide-2 (GLP-2) Agonist Product
 Table 74. Takeda Pharmaceuticals Recent Developments/Updates
 Table 75. Key Raw Materials Lists
 Table 76. Raw Materials Key Suppliers Lists
 Table 77. Glucagon-like Peptide-2 (GLP-2) Agonist Distributors List
 Table 78. Glucagon-like Peptide-2 (GLP-2) Agonist Customers List
 Table 79. Glucagon-like Peptide-2 (GLP-2) Agonist Market Trends
 Table 80. Glucagon-like Peptide-2 (GLP-2) Agonist Market Drivers
 Table 81. Glucagon-like Peptide-2 (GLP-2) Agonist Market Challenges
 Table 82. Glucagon-like Peptide-2 (GLP-2) Agonist Market Restraints
 Table 83. Research Programs/Design for This Report
 Table 84. Key Data Information from Secondary Sources
 Table 85. Key Data Information from Primary Sources
 Table 86. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Glucagon-like Peptide-2 (GLP-2) Agonist
 Figure 2. Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Share by Type: 2024 & 2031
 Figure 4. Gattex Product Picture
 Figure 5. Revestive Product Picture
 Figure 6. Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Value by Application (2020-2031) & (US$ Million)
 Figure 7. Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Share by Application: 2024 & 2031
 Figure 8. Hospital
 Figure 9. Pharmacy
 Figure 10. Other
 Figure 11. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 12. Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Size (2020-2031) & (US$ Million)
 Figure 13. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales (2020-2031) & (K Units)
 Figure 14. Global Glucagon-like Peptide-2 (GLP-2) Agonist Average Price (USD/Unit) & (2020-2031)
 Figure 15. Glucagon-like Peptide-2 (GLP-2) Agonist Report Years Considered
 Figure 16. Glucagon-like Peptide-2 (GLP-2) Agonist Sales Share by Manufacturers in 2024
 Figure 17. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Share by Manufacturers in 2024
 Figure 18. Global 5 and 10 Largest Glucagon-like Peptide-2 (GLP-2) Agonist Players: Market Share by Revenue in Glucagon-like Peptide-2 (GLP-2) Agonist in 2024
 Figure 19. Glucagon-like Peptide-2 (GLP-2) Agonist Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 20. Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 21. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Country (2020-2031)
 Figure 22. North America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Country (2020-2031)
 Figure 23. United States Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 24. Canada Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 25. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Country (2020-2031)
 Figure 26. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Country (2020-2031)
 Figure 27. Germany Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 28. France Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. U.K. Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. Italy Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Russia Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Asia Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Region (2020-2031)
 Figure 33. Asia Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Region (2020-2031)
 Figure 34. China Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. Japan Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. South Korea Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. India Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. Australia Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. China Taiwan Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Indonesia Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Thailand Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Malaysia Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Latin America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Country (2020-2031)
 Figure 44. Latin America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Country (2020-2031)
 Figure 45. Mexico Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Brazil Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Argentina Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Country (2020-2031)
 Figure 49. Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Country (2020-2031)
 Figure 50. Turkey Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Saudi Arabia Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. UAE Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Global Sales Market Share of Glucagon-like Peptide-2 (GLP-2) Agonist by Type (2020-2031)
 Figure 54. Global Revenue Market Share of Glucagon-like Peptide-2 (GLP-2) Agonist by Type (2020-2031)
 Figure 55. Global Glucagon-like Peptide-2 (GLP-2) Agonist Price (USD/Unit) by Type (2020-2031)
 Figure 56. Global Sales Market Share of Glucagon-like Peptide-2 (GLP-2) Agonist by Application (2020-2031)
 Figure 57. Global Revenue Market Share of Glucagon-like Peptide-2 (GLP-2) Agonist by Application (2020-2031)
 Figure 58. Global Glucagon-like Peptide-2 (GLP-2) Agonist Price (USD/Unit) by Application (2020-2031)
 Figure 59. Glucagon-like Peptide-2 (GLP-2) Agonist Value Chain
 Figure 60. Channels of Distribution (Direct Vs Distribution)
 Figure 61. Bottom-up and Top-down Approaches for This Report
 Figure 62. Data Triangulation
 Figure 63. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Novocure

SIMILAR REPORTS

Teduglutide Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Teduglutide Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
GLP Analogs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Antidiabetic Glucagon like Peptide 1 Agonists Market Research Report 2025
Global Glucagon Like Peptide 1 GLP 1 Agonists Market Research Report 2025
Global Glucagon like peptide 1 GLP 1 based Therapies Market Research Report 2025
Global GLP 1 Agonists for Obesity Market Research Report 2024
Global Oral GLP 1 Agonist Market Research Report 2024
Global GLP 1 Agonist Injection Market Research Report 2024
Liraglutide Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global GLP 1 Weight Loss Injection Market Research Report 2024
GLP 1 Analogues Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global GLP 1 Agonists for the Treatment of both Diabetes and Obesity Market Research Report 2024
Global GLP 1 Receptor Agonist Drugs Market Research Report 2024
Global GLP 1 Weight Loss Pill Market Research Report 2024
Global GLP 1RA Therapy Market Research Report 2024
Global Liraglutide for The Treatment of Diabetes and Obesity Market Research Report 2024
Global GLP 1 Drug Peptide API Market Research Report 2024
Global Repaglinide Tablets Market Research Report 2024
Global Exenatide Market Insights Forecast to 2030
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions